Clinical trials: G-CSF
Leukemia, Lymphoma
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00002718
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer, Lung Cancer
Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00021333
- Testing
- filgrastim, cisplatin, paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fox Chase Cancer Center
Graft Versus Host Disease, Leukemia
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00002833
- Testing
- Filgrastim, Cladribine, Cyclosporine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
The purpose of this study is to determine whether it is safe and effective to collect peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after administration of plerixafor.
- Trial name
- NCT01042717
- Testing
- Plerixafor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Shi, Patricia, M.D.
Healthy Allogeneic Donors, Granulocyte Colony-stimulating Factor (G-CSF) Mobilized
Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®
The study will determine the advantage of the Spectra Optia® IDL set compared to the standard collection set for collection of peripheral blood progenitor cells using the Spectra Optia® apheresis system.
- Trial name
- optiMaL (NCT01901458)
- Testing
- Spectra Optia® IDL-Set, Spectra Optia® Collection Set
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Infertility
Diafert® for Embryo Selection and Fertility Improvement
Prospective, single-center, single-blind, randomized, controlled, two-arm, interventional study.
- Trial name
- DESTINy (NCT02593461)
- Testing
- Daifert, Control Group
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Forest Laboratories
Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Allo-HSCT is the most effective way to cure MDS and AML secondary to MDS. At present, the best conditioning regimen for MDS and AML secondary to MDS undergoing allo-HSCT remains in discussion.
- Conditions
- Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT04713956
- Testing
- Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU)
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Peripheral T-Cell Lymphoma
CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation
- Trial name
- NCT01806337
- Testing
- Alemtuzumab
- Volunteers
- 41 people
- Sponsor
- University of Göttingen
Hematologic Malignancies
G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome
The purposes of this study are: To examine the engraftment rate in patients receiving in vivo T-cell-depleted G-CSF stimulated bone marrow from partially mismatched related donors.
- Trial name
- G-CSF PMRD (NCT00228813)
- Testing
- Granulocyte Colony Stimulating Factor
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Emory University
Fertility Disorders
Human Chorionic Gonadotropin Versus Granulocyte Colony Stimulating Factor in Increasing Pregnancy Rate in ICSI
Intrauterine Granulocyte colony stimulating factor (GCSF) was compared with intrauterine Human Chorionic Gonadotropin (HCG) in increasing clinical pregnancy rate as a primary outcome and ultrasound imaging of gestational sac as a…
- Trial name
- NCT04606082
- Testing
- Granulocyte Colony Stimulated Factor, Human Chorionic Gonadotropins
- Volunteers
- 200 people
- Sponsor
- Al-Azhar University
Myelodysplastic Syndromes
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00503880
- Testing
- filgrastim, clofarabine, cytarabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Nebraska
Sarcoma
Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00002539
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- 16 sites in Belgium, Denmark and 6 more
- Volunteers
- 214 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Ovarian Neoplasms
A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients
This is a Phase I study which addresses the feasibility and toxicity of adding taxol to the two drug combination which now comprises the standard of care in newly diagnosed advanced stage ovarian cancer, cisplatin and…
- Trial name
- NCT00001272
- Testing
- taxol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
ST Elevation Myocardial Infarction
Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
The goal of this phase 3, randomized, double-blind, placebo-controlled clinical trial is to explore the safety and efficacy of dutogliptin administered subcutaneously (SC) in co-administration with filgrastim in adult patients…
- Trial name
- HEAL-MI (NCT05881382)
- Testing
- Dutogliptin + Filgrastim
- Volunteers
- 4,100 people
- Sponsor
- Recardio, Inc.
HIV Infections
A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients
The purpose of this study is to examine how the level of HIV is reduced in the blood when anti-HIV therapy is initiated. This study will also evaluate whether adding GM-CSF or IL-12 to the anti-HIV drug regimen will increase the…
- Trial name
- NCT00000896
- Testing
- Indinavir sulfate, Lamivudine/Zidovudine, Hepatitis A Vaccine (Inactivated)
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Myeloblastic Leukemia
Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia
Second-line induction therapy with fludarabine, idarubicin, cytarabine,Granulocyte colony-stimulating factor (G-CSF) and plerixafor, in patients with relapsed or refractory Acute Myeloblastic Leukemia (AML) aged 65 or younger.
- Trial name
- NCT01435343
- Testing
- fludarabine, Idarubicin, cytarabine
- Where
- 10 sites in Spain
- Volunteers
- 55 people
- Sponsor
- PETHEMA Foundation
Women Infertility
G-CSF Administration in IVF in a Preferable Preceptive Endometrium Score
This is a controlled preminary trial intended to increase the implantation rate of IVF cycles, by using more than one known procedure, endometrial scratching, evaluating the status of the adhesive factors as αVβ3 integrin…
- Trial name
- NCT03163862
- Testing
- Endometrial scratch, G-CSF administration, Saline Solution
- Volunteers
- 100 people
- Sponsor
- Istishari Arab Hospital
Infertility, Female
Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF
The purpose of this study is to investigate the effect of G-CSF on endometrial thickness in women who have failed reaching minimal endometrial thickness by standard treatments, to assess how many reach embryo transfer and what…
- Trial name
- NCT01202643
- Testing
- G-CSF, Saline
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Center for Human Reproduction
Anemia, Leukemia
Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as leridistim and filgrastim increase the number of immune cells found in…
- Conditions
- Anemia, Leukemia, Neutropenia, Thrombocytopenia
- Trial name
- NCT00004215
- Testing
- filgrastim, leridistim, cytarabine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematological Malignancy, Neutropenia
Effect of Body Mass on Filgrastim Pharmacokinetics
Studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. This study will use blood samples taken at different time points for patients taking Neupogen to determine if higher…
- Trial name
- NCT01719432
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Aaron Cumpston, PharmD, BCOP